Streamlining screening to treatment: The Hepatitis C cascade of care at Kaiser Permanente Mid-Atlantic States

default

Streamlining screening to treatment: The Hepatitis C cascade of care at Kaiser Permanente Mid-Atlantic States

Authors

Jonas, M. C.,Rodriguez, C. V.,Redd, J.,Sloane, D. A.,Winston, B. J.,Loftus, B. C.

Citation
2016
Clinical Infectious Diseases

62

10
1290-1296
Type
Prospective cohort
Virus targets
Hepatitis B
Hepatitis C
Other targets
HIV
Interventions
HBV testing and linkage to care
HCV testing and linkage to Care
Linkage to care
Screening and diagnosis
Testing
Setting
National
Target populations
General Population
Country of development
United States of America
Target location
United States of America
DOI
10.1093/cid/ciw086
Testing strategy
Laboratory-based antibody test,Laboratory-based PCR/RNA (confirmatory) test
Laboratory-based antibody test
Laboratory-based PCR/RNA (confirmatory) test
Countries of included studies
United States of America

Health outcomes

Linkage to care

Testing strategy

Laboratory-based antibody test,Laboratory-based PCR/RNA (confirmatory) test

Abstract

Hepatitis C virus (HCV) screening is recommended for patients at risk and/or born during 1945-1965, but screening gaps persist. This new program screens target populations and enhances care linkage for chronically HCV-infected patients. Kaiser Permanente Mid-Atlantic States created a comprehensive HCV screening pathway, supported by a HCV care coordinator. The testing pathway includes HCV antibody (Ab), automatic HCV RNA for Ab-positive patients, coinfection and liver health tests, vibration-controlled transient elastography (VCTE), and a physician referral. A total of 11 200 patients were screened; 3.25% were HCV Ab positive, and 100% of Ab-positive patients received HCV RNA testing. Of HCV Ab-positive patients, 75.9% had chronic HCV, of which 80.8% underwent VCTE. HCV diagnosis was communicated to 94% of patients, and 70.9% had HCV documented in the electronic health record. The pathway shows promise in closing gaps, including improving HCV RNA testing, communicating diagnoses, and assessing liver fibrosis. Improved testing and linkage could increase curative treatment access. Copyright © The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America.

Page updated

22 Jan 2021